Elevated Insights

// Aug 2026

When Should You Engage a Cell and Gene Therapy CDMO? Earlier Than You Think.

By: Yogesh Waghmare, Senior Director, MSAT

View Insight

// Aug 2026

Partner Case Study: Accelerating CAR T-Cell Therapy Manufacturing for Autoimmune Disease

By: ElevateBio

View Insight

// Aug 2026

Targeted Gene Insertion Needs More Than One Tool

By: David Wiley, Director, Nucleic Acid Technology

View Insight

// Aug 2026

How Can AI-Directed Protein Engineering Improve Genomic Medicines?

By, Gavin Ellis, Senior Scientist, Translational Biology

View Insight

// Aug 2026

Can Lipid Nanoparticles (LNPs) Replace Electroporation for T-Cell Engineering?

By: Xiuying Li, Ph.D., Senior Scientist, Technology Development

View Insight

// Jul 2026

Rapid Release Testing Starts With Faster Contaminant Detection

By: Gary Sommerville Ph.D., Principal Scientist, NGS, Technical Services

View Insight

// Jul 2026

The Next Base Editors Will Be Engineered, Not Found

By, Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Jul 2026

What Makes a Base Editor Potent and Specific Enough for Therapeutic SNP Correction?

By, Sean Crosson, Senior Scientist, Translational Biology

View Insight

// Jul 2026

Scaling Advanced Therapies and U.S. Biomanufacturing

View Insight

// Jun 2026

From Nature-Limited to AI-Designed: The Future of Gene Editing

By, Amy Pooler, Chief Scientific Officer and Matt Nethery, Principal Data Scientist, Computational Biology

View Insight

// Feb 2026

From Innovation to Impact: Building on Pittsburgh’s Legacy to Industrialize Advanced Therapies

Katie Shannon, VP, Site Head, BaseCamp Pittsburgh

View Insight

// Feb 2026

10 Questions to Ask When Choosing a Cell Therapy CDMO

Mike Paglia, Chief Technology Officer

View Insight